News

Detailed price information for Astrazeneca Plc ADR (AZN-Q) from The Globe and Mail including charting and trades.
Johnson & Johnson’s stock rose 2.4% in premarket trading, enough to pace the Dow Jones Industrial Average’s early gainers.
The health sector is witnessing notable developments. Bristol Myers and Pfizer are offering Eliquis at a discounted rate.
This week's dividend activity included increased payouts from Citigroup (NYSE:C) and Duke Energy (DUK) as well as ...
Analysts expect Johnson & Johnson to report an earnings per share (EPS) of $2.67. Johnson & Johnson bulls will hope to hear ...
Johnson & Johnson shows steady growth in Q2, driven by medtech and oncology, yet talc litigation overshadows. Click for my ...
The board of directors of Royalty Pharma plc (Nasdaq: RPRX) has approved the payment of a dividend for the third quarter of 2025 of $0.22 per Class A ordinary share. The dividend will be paid on ...
Johnson & Johnson shares jumped to their highest price in more than three months as the US-based healthcare group shrugged ...
The healthcare industry offers many attractive dividend investments. Both Johnson & Johnson as well as Pfizer have a positive outlook.
The CDC has approved eligibility guidelines for the Pfizer vaccine booster. Recommendations for Moderna and Johnson & Johnson could come soon.
Comparing the COVID-19 vaccines: If you have a choice, which one should you get? Pfizer, Moderna and Johnson & Johnson are all safe and effective, but there are some differences.
CDC recommends Pfizer, Moderna vaccines over Johnson & Johnson, citing rare blood-clot issue Nine deaths, several dozen cases, have been confirmed in connection with the vaccine.